Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

An estimated 24,499 people visited the ED for adverse events related to semaglutide in the 2 years after its approval for ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

Compared with other antidiabetic medications, semaglutide was linked to a significantly lower risk of opioid overdose in ...

The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

New Delhi: Torrent Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug ...

Big compounders will have until May 22 to stop producing and dispensing compounded semaglutide, while smaller, state-run ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

The decision came in response to a February lawsuit from a compounding industry group against the FDA's decision that there ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight ...

Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!